Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bare Escentuals grows in 2008

This article was originally published in The Rose Sheet

Executive Summary

Overall retail sales of prestige cosmetics shrank 6% in the fiscal 2008 fourth quarter, but Bare Escentuals' sales in the channel were up 2%; CEO Leslie Blodgett attributes the standout performance to the "unique strength of our brand and our deep connection with our loyal consumer base." Mineral makeup firm remains focused on protecting that consumer base, attracting new customers, expanding distribution domestically and abroad, and simplifying company organizational structure in recessed economy, firm says in a Feb. 26 earnings call. Net Q4 sales increased 2% to $147.1 mil.; net income was $24.6 mil., down 9%. Firm plans busy 2009 launch schedule, beginning with a mascara from its Buxom brand; new mascara under its bareMinerals umbrella will debut in summer - "our first step to growing a meaningful eye business for the bareMinerals brand," Blodgett says. Company will also launch a new bareMinerals matte foundation "enhanced with RareMinerals and supported by strong clinical results," according to the exec. Firm intends to lure new customers via increased sampling, involvement in social networking Web sites, and promotion of makeup kits. Bare Escentuals booked $556.2 mil. in net sales for the year, and recorded $98 mil. in net income, up 9% and 11% from 2007

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel